Please use this identifier to cite or link to this item:
Title: Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease
Authors: Elmar A. Joura
Kevin A. Ault
F. Xavier Bosch
Darron Brown
Jack Cuzick
Daron Ferris
Suzanne M. Garland
Anna R. Giuliano
Mauricio Hernandez-Avila
Warner Huh
Ole Erik Iversen
Susanne K. Kjaer
Joaquin Luna
Dianne Miller
Joseph Monsonego
Nubia Munoz
Evan Myers
Jorma Paavonen
Punnee Pitisuttithum
Marc Steben
Cosette M. Wheeler
Gonzalo Perez
Alfred Saah
Alain Luxembourg
Heather L. Sings
Christine Velicer
Medizinische Universitat Wien
University of Kansas Medical Center
Institut d'Investigacio Biomedica de Bellvitge
Indiana University School of Medicine Indianapolis
Barts and The London School of Medicine and Dentistry
Augusta University
University of Melbourne
Moffitt Cancer Center
Instituto Nacional de Salud Publica
University of Alabama
Universitetet i Bergen
Kraeftens Bekaempelse
Kobenhavns Universitet
Fundación Universitaria Sanitas
The University of British Columbia
Institut du Col
National Institute of Cancer
Duke University Medical Center
Helsinki University Hospital
Mahidol University
Institut National de Sante Publique Du Quebec
University of New Mexico Health Sciences Center
Merck & Co., Inc.
Universidad del Rosario
Keywords: Medicine
Issue Date: 1-Jan-2014
Citation: Cancer Epidemiology Biomarkers and Prevention. Vol.23, No.10 (2014), 1997-2008
Abstract: Background: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/ 16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, and the attribution of these HPV types in cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. Methods: A total of 10,656 women ages 15 to 26 years and 1,858 women ages 24 to 45 years were enrolled in the placebo arms of one of three clinical trials of a quadrivalent HPV vaccine. We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes, as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine. Results: The cumulative incidence of persistent infection with≥1 of the seven high-risk types included in the 9-valent vaccine was 29%, 12%, and6%forwomen ages 15 to 26, 24 to 34, and 35 to 45 years, respectively.Atotal of 2,507 lesions were diagnosed as CIN or AIS by an expert pathology panel. After adjusting for multiple-type infected lesions, amongwomen ages 15 to 45 years, these seven high-risk types were attributed to 43% to 55% of CIN1, 70% to 78% of CIN2, 85% to 91% of CIN3, and 95% to 100% of AIS lesions, respectively. The other tested types (HPV35/39/51/56/59) were attributed to 23% to 30% of CIN1, 7% to 14% of CIN2, 3% to 4% of CIN3, and 0% of AIS lesions, respectively. Conclusions: Approximately 85% or more of CIN3/AIS, >70% CIN2, and approximately 50% of CIN1 lesions worldwide are attributed to HPV6/11/16/18/31/33/45/52/58. Impact: If 9-valent HPV vaccination programs are effectively implemented, the majority of CIN2 and CIN3 lesions worldwide could be prevented, in addition to approximately one-half of CIN1.
ISSN: 10559965
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.